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Abstract
Purpose: To assess long-term outcomes in children with high risk ALL treated according to 
American and European protocols.
Methods: A group of 74 children treated with New York like protocols was compared to a group 
of 45 children treated according to ALLIC-2002. All studied patients had initial WBC ≥ 50 × 109/L. 
NY consisted of very intensive, repeated multidrug cycles administered over the period of 3 years, 
whereas ALLIC provided intensive multidrug chemotherapy for 7 months in IRG and 9 months in 
HRG, followed by maintenance therapy applied for up to two years of treatment.
Results: After more than 5 years of follow-up 57 (77%) of NY and 33 (73%) of ALLIC patients are 
alive in first complete remission. There were 13 (17.6%) and 9 (20%) relapses as well as 16 (9.4%) 
and 7 (15.6%) deaths respectively. Five-year EFS and OS in NY were 77%/78% and in ALLIC 
73%/83.6% respectively. HSCT after relapse was performed in 1 patient from NY. There were 13 
HSCT performed in I RC and 3 after relapse in ALLIC group. Relapses and other adverse events 
occurred mostly in patients with WBC ≥ 100 × 109/L.
Conclusion: Generally, the achieved results were satisfactory and comparable to those observed 
in other centers at that time. OS in the NY patients was inferior mainly due to lack of effective 
HSCT procedures commonly available for ALLIC patients. Despite higher intensity of NY we did 
not observe more fatal events not related to the relapse; however the frequency of late side effects 
in NY treated patients was probably higher. The criterion of initial leukocytosis WBC ≥ 100 × 109/L 
still indicates children with high risk of relapse and death, although modern risk criteria (mainly 
MRD and genetic evaluation) are much better for adequate risk stratification.
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ALL: Acute Lymphoblastic Leukemia; ALLIC: ALLIC-2002 protocol; BFM: Berlin Frankfurt 
Munster Study Group; BM: Bone Marrow; BM M1: Blast Cells <5% in Bone Marrow; BM M2: Blast 
Cells 5: 25% in Bone Marrow; BM M3: Blast Cells >25% in Bone Marrow; CCG: Children’s Cancer 
Group; CNS-1: Central Nervous System free of Leukemia; CNS-2: Central Nervous System free of 
Leukemia, contaminated with blood; CNS-3: Involvement of Central Nervous System in Leukemic 
Disease; CR: Complete Remission; EFS: Event Free Survival; Gy: Gray; HR: High Risk; HRG: 
High-Risk Group; HSCT: Hematopoietic Stem Cell Transplantation; IR: Intermediate Risk; IRG: 
Intermediate Risk Group; MRD: Minimal Residual Disease; NY: New York protocol; OS: Overall 
Survival; WBC: White Blood Cells
Introduction
One of the most important factors influencing the efficacy of the treatment of Acute 
Lymphoblastic Leukemia (ALL) patients is adjusting the intensity of therapy to risk criteria. The 
risk criteria have been changed within the time between the first attempts of treatment of ALL 
patients and nowadays.
We compared the outcome of two groups of patients with ALL and initial leukocytosis over 
50 × 109/L treated in the Department of Pediatric Oncology and Hematology in Krakow. One group 
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was treated according to New York-like protocols (1988-2003), 
the other with ALLIC-2002 protocol (2003-2012). The historical 
treatment results in ALL with initial WBC WBC ≥ 50 × 109/L 
on protocols used between 1981 and 1986 in the centers of Polish 
Pediatric Leukemia/Lymphoma Study Group were significantly lower 
than in children with WBC <50 × 109/L (33% vs. 60%) [1]. Therefore, 
in 1988 we introduced modified New York protocol (NY) dedicated 
for those children, first implemented in CCG/USA by Steinherz et al. 
[2]. The inclusion criterion was pediatric ALL with initial leukocytosis 
WBC ≥ 50 × 109/L, which was at that time our only criterion for high 
risk ALL patients. Patients with WBC <50,000 × 109/L at diagnosis 
were treated according to less intensive BFM protocol. In 2003 we 
stopped recruiting to the New York protocol and started ALLIC-2002 
established by BFM-group (ALLIC) for all the ALL patients. Instead 
of the single risk group criterion of initial WBC for HR patients the 
multiple criteria were introduced to the risk stratification. The criteria 
for high risk group were: genetic abnormalities (t 9;22 and 4;11), 
poor prednisone response, initially IR patients with BM M3 in day 
15, BM M2 or M3 in 33 day, blast cells in mediastinal tumor or in 
testicles after 33 day of treatment [3,4]. The last patient recruited to 
ALLIC was diagnosed on Dec 22nd, 2012. The idea of NY was very 
intensive chemotherapy from the very beginning to the end of 3-years 
lasting treatment, whereas ALLIC provided 7-days steroids prophase 
followed by intensive multidrug i.v. chemotherapy during induction 
of remission, consolidation and reinduction (which altogether lasted 
7 months in IRG and 9 months in HRG) and for the rest of the 
two-year treatment period less intensive maintenance therapy had 
been used (mercaptopurine and methotrexate given orally). Cranial 
irradiation was given for all NY patients (18 Gy as prophylaxis and 
24 Gy in CNS positive patients), whereas only the selected group of 
ALLIC patients underwent this procedure (12 Gy for selected CNS 
1/2 patients, 18 Gy for all CNS 3 patients). The details concerning 
intensity of treatment are provided in Table 1. The aim of our study 
was to compare the treatment results among children with initial 
WBC ≥ 50 × 109/L treated with those protocols and being in follow-
up for more than 5 years.
Material and Methods
Within the group of 235 children treated according to 
ALLIC-2002 there were 45 (19.14%) with initial WBC ≥ 50 × 109/L, 
among them 23 with initial WBC ≥ 100 × 109/L. There were 35 boys 
and 10 girls, aged from 1.4 to 17.5 years (median 7.3 years). The initial 
WBC ranged from ≥ 50 × 109/L to 863 × 109/L (median 100.8 × 109/L). 
We compared these results with those obtained from 22.06.1988 to 
10.03.2003 according to modified New York protocols for children 
with ALL and WBC at diagnosis ≥ 50 x 109/L. The NY group consisted 
of 74 patients, 42 boys and 32 girls, aged 1.7 to 18.6 (median 5.3) 
years, with; WBC at diagnosis ranged from 50.6 × 109/L to 764 × 
109/L (median 122 × 109/L). The characteristic of studied groups is 
presented in Table 2.
Statistical analysis
Overall Survival (OS) and Event Free Survival (EFS) were 
calculated using the Kaplan-Meier method. OS was defined as the 
time from diagnosis to death from any cause; patients alive or lost to 
follow-up were censored at the date they were last known alive. EFS 
was defined as the time from diagnosis to disease progression, relapse 
or death from any cause. Patients who were alive without disease 
progression or relapse were censored at the time they last were seen 
alive and event-free. For comparisons of Kaplan-Meier curves we 
used the log-rank test. All statistical analysis were performed using 
STATISTICA 13 software.
Results
In the ALLIC (45 patients) 1 died without achieving remission, 
2 died in I CR due to sepsis, 9 patients relapsed: (4 died, 5 are alive 
Drugs (mg/m2) New York ALLIC-2002-IRG ALLIC-2002-HRG
prednisone 20 220 1680 1680
dexamethasone  210 810
VCR 70.5 12 18
DNR  120 120
DOXO 540 120 120
L-ASPA 1 200 000 80 000 380 000
CY 18 000 3 000 5 000
ARA-C 4560 1800 9 800
6-MP  3080 + 25 900 1740 + 22050
6-TG 20 340 840 840
Mtxi.v. 4400 8000 (BCP), 20 000(T) 20 000
VDS   12
IFO   8 000
VP-16   1 000
Mtxp.o.  20 × 74 20 × 63
Mtxith 8/10/12 × 6 8/10/12 × 11 8/10/12 × (13)
ARA-C ith 30/m2 × 6  × 6
Soludacith 15/m3 × 6  × 6
Table 1: Cumulative doses of drugs used in New York and ALLIC-2002 protocols.
RT 18 Gy 12 Gy (selected pts)/18 Gy 12 Gy or HSCT/18 Gy
Protocol/Results New York ALLIC-2002
Patients number 74 45
Gender- male/female 42/32 35/10
Age (median) years 1.4-17.5 (7.3) 1.7-18.6 (5.3)
Initial WBC (median)/µl 50.000-863.000 (100.81) 50.600-764.000 (122)
WBC ≥ 100 000/µl 48 (64.8%) 23 (51.1%)
Relapses
≥ 50 000/µl 13 9
≥ 100 000/µl 11/13 04/9
Deaths
≥ 50 000/µl   
Without IRC 3 1
In IRC 1 2
In relapse 12 4
≥ 100 000/µl   
Without IRC 3 0
In IRC 1 2
In relapse 10 3
Alive (%) 57 (74)- in I CR
33 (45)- in I CR (10 after 
HSCT)
1 in II CR after HSCT 5 in II CR
5-year EFS 77% 73%
5-year OS 78% 83.60%
Table 2: Characteristic of NY and ALLIC patients.
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in II CR). Thirty three (73.3%) patients are alive in I CR (including 
10 after HSCT). Among 23 patients with initial leukocytosis ≥ 100 × 
109/L: 4 patients relapsed (3 of them died, one remains in I CR) and 2 
died in I CR. In the group of 22 patients with WBC lower than 100 × 
109/L we observed 5 relapses (one patient died) and 1 death without I 
CR. According to the protocol risk criteria 24 patients (20 boys and 4 
girls) were assigned to IRG, and 21 (15 boys and 6 girls) to HRG. We 
observed higher WBC in HRG (range 50 × 109/L: 836 × 109/L, median 
132 × 109/L) than in IRG (range 51 × 109/L: 440 × 109/L, median 82 
× 109/L). Among 24 patients assigned to IRG one boy died without 
achieving I CR, 4 patients (2 girls and 2 boys) experienced relapse. All 
relapsed children live in II CR. Within 21 HRG patients there were 2 
deaths in I CR and 5 relapses (4 boys and 1 girl); only one relapsed 
patient lives in II CR, the remaining 4 died due to progression of the 
disease. We observed significantly better treatment results in IRG 
patients compared to HRG, with EFS 78.7% and 65,9% (p=0.342) and 
OS 95.8% and 70% (p=0.34), respectively.
Analyzing the results obtained between Jun 22nd, 1988 and Mar 
10th, 2003 using modified New York protocols we observed the 
following: Out of 74 NY patients 3 died without I CR, 1 died in I CR, 
and 13 relapsed. Only 1 relapsed patient lives in II CR after HSCT, 
the remaining 12 died due to progression of the disease. The majority 
of patients are alive: 57 (77%) in I CR, 1 in II CR. Relapses occurred 
mostly in patients with WBC ≥ 100 × 109/L (11 patients). Other adverse 
events (all four deaths without or in I CR) occurred also (exclusively) 
among patients with initial WBC ≥ 100 × 109/L. We assessed EFS and 
OS in ALLIC and NY patients as well as the influence of WBC, age, 
gender and immunophenotype on EFS in both groups (Figures 1-4). 
We also compared the EFS and OS in ALLIC patients assigned to 
IRG and HRG. The results are presented in Table 3 and on Kaplan-
Meier survival curves (Figure 1). We found the differences between 
compared groups (especially regarding initial WBC and different risk 
groups in ALLIC) (Figure 5 and 6), but no significance was found 
with the use of log rank test, due to limited number of patients. No 
significant influence of age, gender, WBC, immunophenotype on 
EFS was found in either group with the use of log rank test. The only 
significant difference was found in OS between IRG and HRG ALLIC 
patients (0.958 and 70%, respectively, p=0.03257).
There were no significant differences in the results of treatment 
between two studied groups of patients. In the first period (on New 
York protocols) only 1 patient had HSCT performed after relapse. In 
the later period HSCT was performed in I CR in 13 patients (12 boys 
and 1 girl). Only 3 out of 13 patients experienced relapse: 2 of them 
died, 1 live in II CR. Three out of 9 patients who experienced relapse 
had subsequent HSCT: One of them died, 2 are alive in II RC. There 
Protocol/Parameter New York p (log rank) ALLIC-2002 p (log rank)
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0.34
HRG   65.90%
Table 3: Results of analysis of influence of selected parameters on EFS.
Protocol/Parameter ALLIC-2002 p (log rank)




Table 4: Results of analysis of influence of selected parameters on OS.
EFS
 New York, EFS = 77%, no of pts 74
 ALLIC-2002, EFS = 73%, no of pts 45

























Figure 1: Kaplan-Meier survival curve: EFS in NY and ALLIC.
A. Kaplan-Meier survival curve: EFS and OS, comparison of NY and ALLIC.
B. Kaplan-Meier survival curve: EFS and OS, comparison of NY and ALLIC 
depending on WBC.
C. Kaplan-Meier survival curve: EFS andOS, comparison of NY and ALLIC 
depending on risk groups.
EFS: Event-Free Surviva; OS: Overall Survival; NY: New York protocol; 
ALLIC: ALLIC-2002 protocol; WBC: White Blood Cells; IRG: Intermediate 
Risk Group; HR: High Risk Group
OS
 NY, OS = 78%, no of pts 74
 ALLIC-2002, OS = 83,6%, no of pts 45
























Figure 2: Kaplan-Meier survival curve: OS in NY and ALLIC.
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were no significant differences among New York and ALLIC-2002 
patients regarding event free survival. Five-year EFS in New York 
group was 77% vs. 73% in ALLIC-2002 group (p=0.75). However, 
we noticed higher 5-year OS in ALLIC-2002 group when compared 
to New York (83.6% and 78%, respectively, p=0.462), which was the 
effect of successful HSCT procedures performed in relapsed patients 
in the later period of treatment.
Discussion
In late 80-s forced by dismal treatment results in children with 
initial WBC ≥ 50 × 109/L on BFM protocols another approach was 
urgently needed. In 1987 the Steinhertz group reported 5-year EFS 
reaching 70% in such group of patients. It was the time of tendency 
to intensification of treatment protocols. The idea of maintaining 
of high intensity for 3 years in very high risk according to that time 
stratification was very promising. Necessity to cure as much children 
as possible seemed to be more important than late effects we were not 
fully aware of. It was kind of courage to introduce high dose chemo 
EFS - NY
 WBC 50 000-99 999/ul, EFS = 92,3%, no of pts 26
 WBC >= 100 000/ul, EFS = 68,7%, no of pts 48

























Figure 3: Kaplan-Meier survival curve: EFS in NY depending on WBC.
EFS - ALLIC-2002
 WBC > 100 000/ul, EFS = 72,1%, no of pts 23
 WBC 50 000 - 99 999/ul, EFS = 73,9%, no of pts 22

























Figure 4: Kaplan-Meier survival curve: EFS in ALLIC depending on WBC.
EFS - ALLIC-2002
 IRG, EFS = 78,7%, no of pts 24
 HRG, EFS = 65,9%, no of pts 21
























Figure 5: Kaplan-Meier survival curve: EFS in ALLIC depending on risk 
group.
OS - ALLIC-2002
 IRG, EFS = 95,8%, no of pts 24
 HRG, EFS = 70%, no of pts 21

























Figure 6: Kaplan-Meier survival curve: OS in ALLIC depending on risk group.
in children with high WBC and often bulky disease. Since 2003 the 
BFM: Based protocol came back for high risk children as the results 
were comparable and the awareness of late-effects was common. 
Stratification of ALLIC was based on adjustment of risk group to 
response to therapy and genetic abnormalities. Therefore patients 
with WBC ≥ 50 × 109/L not necessarily were assigned to HRG.
New York protocol, being much more intensive than ALLIC-2002, 
was conducted in an earlier period, when the quality of supportive 
care was inferior. Also, diagnostic procedures at that time were rather 
limited: The microscopic assessment and immunophenotyping, 
without wide genotyping and MRD assessment. The only risk 
criterion was initial WBC [5]. Generally, the achieved results were 
satisfactory with 5-year EFS 77%, comparable to those observed in 
other centers [6-8]. In the NY patients 5-year OS was inferior to the 
results obtained in ALLIC, mainly due to effective HSCT procedures 
provided for selected HR ALLIC patients. Very intensive NY was 
beneficial at that time for some patients who most probably would 
experience relapse and died with less intensive protocol. However, 
there were also children who could have been cured with less 
intensive therapy if more sophisticated risk criteria, mainly MRD and 
genetic evaluation, would have been available [9-12]. The results of 
ALLIC confirmed it, because we could observe significant differences 
Szymon Skoczen, et al., Clinics in Oncology - General Oncology
Remedy Publications LLC., | http://clinicsinoncology.com/ 2020 | Volume 5 | Article 17595
among treatment results in IRG and HRG, regarding our selected 
patients with initial WBC ≥ 50 × 109/L, with EFS 78.7% and 65.9% 
(p=0.34), and OS 95.8% and 70% (p=0.03257), respectively. The 
differences among patients with initial WBC 50 × 109/L: 100 × 109/L 
and ≥ 100 × 109/L on ALLIC were less pronounced (EFS 73.9% and 
72.1%, respectively, p=0.91). Despite higher intensity of NY we did 
not observe more fatal events not related to the relapse, compared to 
ALLIC-2002 group (3/45 vs. 4/74), however the frequency of late side 
effects in NY treated patients was probably higher.
In studied groups we obtained better EFS on NY then on ALLIC. 
One can only speculate that results on NY would have been even 
better if HSCT and modern supportive treatment had been available 
at that time. On the other hand survival curves for NY patients will 
be probably decreased within the time due to late effects in highly 
pretreated cohort.
Therefore, despite a good outcome we are aware of the fact that 
very intensive chemotherapy conducted for a long period of time, as 
in NY protocol, has to be associated with high prevalence of severe 
and long lasting side effects, increasing within the time, in many 
patients [13]. Doubtfully, survivors treated with NY should be strictly 
follow-up for the entire life. Unfortunately the adult health service is 
not aware of survivors care and insufficient what makes their future 
uncertain.
Conclusions
The criterion of WBC 50 × 109/L stratifying children with ALL to 
HRG was useful in the late eighties of the last century.
The results of NY were comparable to ALLIC.
HSCT improved survival in children with WBC >100,000/µl.
Health consequences in heavily pretreated children are and will 
be high.
Modern ALL stratification decreases treatment intensity and 
future late effects of therapy [14].
In late 80s, American protocol strategy for children with ALL and 
with WBC >50,000/µl was beneficial from the point of view of cure 
rates comparing to European protocols.
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